(PR1E) Amundi Index Solutions - Ratings and Ratios
Large-Cap Equity, Blend Equity
Description: PR1E Amundi Index Solutions
Amundi Index Solutions - Amundi Prime Europe UCITS ETF DR (XETRA:PR1E) is an exchange-traded fund that tracks the Morningstar Developed Markets Europe TME NR EUR Index, providing investors with broad exposure to large-cap European equities. The fund is domiciled in Germany and is designed to deliver a blend of European stocks, making it a diversified investment option for those seeking to tap into the European market.
The ETFs investment strategy is centered around replicating the performance of its underlying index, which comprises a selection of European stocks from developed markets. By doing so, it offers investors a low-cost and efficient means of accessing the European equity market. The funds assets under management (AUM) stand at €85.54 million, indicating a moderate level of investor interest.
From a technical analysis perspective, the ETFs price action suggests a bullish trend, with the short-term Simple Moving Average (SMA20) and medium-term Simple Moving Average (SMA50) indicating a positive momentum. The Average True Range (ATR) is relatively low at 1.74%, suggesting that the ETFs price is not experiencing significant volatility. Given the current price of €31.13, the SMA20 at €29.95, and the SMA50 at €29.87, it is likely that the ETF will continue to move upwards, potentially testing the 52-week high of €31.77.
Combining technical and fundamental analysis, a forecast for Amundi Prime Europe UCITS ETF DR can be derived. With the ETFs underlying index tracking the European equity market, and considering the current economic environment, it is likely that the fund will continue to benefit from a positive trend in European stocks. Assuming the AUM continues to grow, and the ETFs tracking error remains minimal, the price is forecasted to reach €32.50 in the short term, representing a potential upside of 4.4% from current levels. However, investors should be cautious of potential risks, including market downturns and changes in investor sentiment.
PR1E ETF Overview
Market Cap in USD | 113m |
Category | Europe Large-Cap Blend Equity |
TER | 0.05% |
IPO / Inception | 2019-01-30 |
PR1E ETF Ratings
Growth Rating | 70.4% |
Fundamental | - |
Dividend Rating | 67.8% |
Return 12m vs S&P 500 | -4.40% |
Analyst Rating | - |
PR1E Dividends
Dividend Yield 12m | 2.64% |
Yield on Cost 5y | 4.50% |
Annual Growth 5y | 11.03% |
Payout Consistency | 95.9% |
Payout Ratio | % |
PR1E Growth Ratios
Growth Correlation 3m | -2.5% |
Growth Correlation 12m | 70.7% |
Growth Correlation 5y | 91.2% |
CAGR 5y | 11.92% |
CAGR/Max DD 5y | 0.61 |
Sharpe Ratio 12m | 1.01 |
Alpha | 0.27 |
Beta | 0.515 |
Volatility | 11.45% |
Current Volume | 0.7k |
Average Volume 20d | 2.1k |
Stop Loss | 30.8 (-3.1%) |
Signal | 1.96 |
What is the price of PR1E shares?
Over the past week, the price has changed by +2.01%, over one month by +2.24%, over three months by +1.78% and over the past year by +10.67%.
Is Amundi Index Solutions a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PR1E is around 32.17 EUR . This means that PR1E is currently overvalued and has a potential downside of 1.23%.
Is PR1E a buy, sell or hold?
What are the forecasts/targets for the PR1E price?
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 35.7 | 12.3% |
PR1E Fundamental Data Overview
Market Cap EUR = 96.4m (96.4m EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = unknown
Revenue TTM is 0, using Net Income TTM 0.0 + Cost of Revenue 0.0 = 0.0 EUR
Beta = 1.01
Revenue TTM = 0.0 EUR
EBIT TTM = 0.0 EUR
EBITDA TTM = 0.0 EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 96.4m EUR (96.4m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = none (FCF TTM 0.0 / Enterprise Value 96.4m)
FCF Margin = unknown (Revenue TTM is 0)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 96.4m / Book Value Of Equity 0.0)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt none)
Taxrate = unknown
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown Debt (none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = none (Debt none / FCF TTM 0.0)
Total Stockholder Equity = unknown
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity none)
RoCE = unknown (Ebit 0.0 / (Equity none + L.T.Debt none))
RoIC = unknown (NOPAT none, Invested Capital 0.0, Ebit 0.0)
WACC = unknown (E(96.4m)/V(0.0) * Re(7.91%)) + (D(none)/V(0.0) * Rd(0.0%) * (1-Tc(none)))
Discount Rate = 7.91% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow 0.0)